Sunshine Biopharma Inc. - Common stock (SBFM)
SBFM moved a median of -0.33% 30 minutes after news, and -1.56% by the close. How SBFM actually reacts to news — the realized, point-in-time move the market made, measured across 178 labeled events over the last three years with zero look-ahead.
SBFM’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.02% | 40% | 171 |
| 30-min | -0.33% | 45% | 177 |
| 60-min | -0.95% | 37% | 177 |
| to close | -1.56% | 35% | 178 |
| Middle 50% of SBFM reactions | -3.13% to +1.29% |
|---|---|
| Median reaction (30-min) | -0.33% |
| Measured reactions | 178 |
Half of all Sunshine Biopharma Inc. - Common stock news events land between -3.13% and +1.29% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when SBFM moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SBFM's baseline. Nothing else.
Recent SBFM events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Sunshine Biopharma Inc. For: Oct 13 | SEC filing · Form 8-K | SEC EDGAR | -7.67% | +0.26% | |
| Form PRE 14C Sunshine Biopharma Inc. For: Oct 14 | SEC filing · Form PRE | SEC EDGAR | -7.67% | +0.26% | |
| Form 8-K Sunshine Biopharma Inc. For: Oct 08 | SEC filing · Form 8-K | SEC EDGAR | +2.93% | -0.66% | |
| Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering | Press release | ACCESS Newswire | +0.30% | -8.90% | |
| Form EFFECT Sunshine Biopharma Inc. | SEC filing · Form EFFECT | SEC EDGAR | -6.38% | -8.51% | |
| Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering | Press release | ACCESS Newswire | -6.38% | -8.51% | |
| Form S-1 Sunshine Biopharma Inc. | SEC filing · Form S-1 | SEC EDGAR | -4.83% | -13.38% | |
| Form DEF 14C Sunshine Biopharma Inc. For: Sep 15 | SEC filing · Form DEF | SEC EDGAR | -2.65% | -2.90% | |
| Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio | Press release | ACCESS Newswire | -1.49% | -7.81% | |
| Form 8-K Sunshine Biopharma Inc. For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | -2.97% | -16.72% | |
| Form PRE 14C Sunshine Biopharma Inc. For: Sep 15 | SEC filing · Form PRE | SEC EDGAR | -2.97% | -16.72% | |
| Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies | Press release | ACCESS Newswire | +0.00% | +0.00% | |
| Form 8-K Sunshine Biopharma Inc. For: Sep 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.91% | |
| Form EFFECT Sunshine Biopharma Inc. | SEC filing · Form EFFECT | SEC EDGAR | -0.88% | -1.75% | |
| Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions | Press release | ACCESS Newswire | +0.76% | -1.75% | |
| Form 8-K Sunshine Biopharma Inc. For: Aug 25 | SEC filing · Form 8-K | SEC EDGAR | +0.76% | -1.75% | |
| Form S-1 Sunshine Biopharma Inc. | SEC filing · Form S-1 | SEC EDGAR | +0.76% | -1.75% | |
| Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer | Press release | ACCESS Newswire | -1.23% | +1.64% | |
| Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market | Press release | ACCESS Newswire | -1.26% | -1.68% | |
| Form 10-Q Sunshine Biopharma Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -2.54% | |
| Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market | Press release | ACCESS Newswire | -4.00% | -18.00% | |
| Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval | Press release | ACCESS Newswire | -1.59% | +3.97% | |
| Form 8-K Sunshine Biopharma Inc. For: Aug 03 | SEC filing · Form 8-K | SEC EDGAR | +2.61% | +1.74% | |
| Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting | Press release | ACCESS Newswire | -1.29% | -7.74% | |
| Form 8-K Sunshine Biopharma Inc. For: Jul 20 | SEC filing · Form 8-K | SEC EDGAR | — | -1.13% | |
| Sunshine Biopharma and University of Arizona Publish Significant New Research Findings | Press release | ACCESS Newswire | -1.11% | -3.89% | |
| Form 8-K Sunshine Biopharma Inc. For: Jul 08 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -4.88% | |
| Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R) | Press release | ACCESS Newswire | +0.48% | +3.88% | |
| Form DEF 14C Sunshine Biopharma Inc. For: Jun 08 | SEC filing · Form DEF | SEC EDGAR | +0.43% | -1.72% | |
| Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R) | Press release | ACCESS Newswire | -1.14% | -7.36% | |
| Form 8-K Sunshine Biopharma Inc. For: May 28 | SEC filing · Form 8-K | SEC EDGAR | -1.14% | -7.36% | |
| Form PRE 14C Sunshine Biopharma Inc. For: May 29 | SEC filing · Form PRE | SEC EDGAR | -1.14% | -7.36% | |
| Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology | Press release | ACCESS Newswire | -0.33% | -15.58% | |
| Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing | Press release | ACCESS Newswire | -9.07% | -15.96% | |
| Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin | Press release | ACCESS Newswire | +1.29% | -6.28% | |
| Form 8-K Sunshine Biopharma Inc. For: May 18 | SEC filing · Form 8-K | SEC EDGAR | -1.82% | -8.18% | |
| Form EFFECT Sunshine Biopharma Inc. | SEC filing · Form EFFECT | SEC EDGAR | -3.39% | -1.15% | |
| Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering | Press release | ACCESS Newswire | +0.55% | -0.59% | |
| Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering | Press release | ACCESS Newswire | -18.52% | -53.21% | |
| Form 10-Q Sunshine Biopharma Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.59% | -16.20% | |
| Form S-1 Sunshine Biopharma Inc. | SEC filing · Form S-1 | SEC EDGAR | +0.01% | -24.13% | |
| Form 8-K Sunshine Biopharma Inc. For: Apr 06 | SEC filing · Form 8-K | SEC EDGAR | -0.97% | -4.00% | |
| Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year | Press release | ACCESS Newswire | -0.94% | +9.43% | |
| Form 10-K Sunshine Biopharma Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.94% | +9.43% | |
| Form NT 10-K Sunshine Biopharma Inc. For: Dec 31 | SEC filing · Form NT | SEC EDGAR | +1.17% | +6.31% | |
| Form 8-K Sunshine Biopharma Inc. For: Mar 06 | SEC filing · Form 8-K | SEC EDGAR | +0.91% | +8.18% | |
| Form DEF 14C Sunshine Biopharma Inc. For: Mar 02 | SEC filing · Form DEF | SEC EDGAR | +0.85% | -1.72% | |
| Form 8-K Sunshine Biopharma Inc. For: Feb 18 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.54% | |
| Form PRE 14C Sunshine Biopharma Inc. For: Feb 18 | SEC filing · Form PRE | SEC EDGAR | +0.00% | -2.54% | |
| Form 8-K Sunshine Biopharma Inc. For: Feb 05 | SEC filing · Form 8-K | SEC EDGAR | -2.27% | -1.64% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SBFM section they belong to.
Where else SBFM is measured.
SBFM earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| SOL GLOBAL INVTS CORP (SOLCF) | 179 | 0.00% | 49% |
| Heartbeam, Inc. (BEAT) | 178 | -0.55% | 43% |
| Cardax, Inc. (CDXI) | 177 | 0.00% | 13% |
| NRC Health (NRC) | 177 | -0.16% | 38% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Sunshine Biopharma Inc. - Common stock's median reaction calculated?
Every labeled SBFM news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 178 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of SBFM's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SBFM's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.